DiaMedica Therapeutics (NASDAQ:DMAC) Stock Rating Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of DiaMedica Therapeutics (NASDAQ:DMAC) from a hold rating to a sell rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

A number of other equities analysts have also recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of DiaMedica Therapeutics in a report on Tuesday, August 11th. Weiss Ratings restated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Thursday, October 15th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $12.00.

DiaMedica Therapeutics Stock Down 5.8%

Shares of NASDAQ DMAC traded down $0.54 during midday trading on Friday, reaching $8.79. 214,091 shares of the company were exchanged, compared to its average volume of 211,040. The stock’s 50-day moving average price is $8.21 and its 200-day moving average price is $7.20. The stock has a market cap of $474.04 million, a P/E ratio of -11.57 and a beta of 0.95. DiaMedica Therapeutics has a one year low of $5.24 and a one year high of $11.00.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.21) EPS for the quarter, meeting analysts’ consensus estimates of ($0.21). On average, equities research analysts anticipate that DiaMedica Therapeutics will post -0.84 EPS for the current year.

Institutional Trading of DiaMedica Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of DMAC. Bank of America Corp DE raised its position in shares of DiaMedica Therapeutics by 62.5% in the 1st quarter. Bank of America Corp DE now owns 42,768 shares of the company’s stock worth $290,000 after acquiring an additional 16,446 shares in the last quarter. AWM Investment Company Inc. lifted its stake in shares of DiaMedica Therapeutics by 80.8% in the 3rd quarter. AWM Investment Company Inc. now owns 65,097 shares of the company’s stock valued at $538,000 after purchasing an additional 29,097 shares during the period. Tocqueville Asset Management L.P. bought a new stake in shares of DiaMedica Therapeutics during the 3rd quarter valued at about $332,000. Renaissance Technologies LLC bought a new stake in shares of DiaMedica Therapeutics during the 1st quarter valued at about $356,000. Finally, Sei Investments Co. boosted its position in shares of DiaMedica Therapeutics by 100.0% during the 1st quarter. Sei Investments Co. now owns 111,320 shares of the company’s stock valued at $754,000 after purchasing an additional 55,660 shares in the last quarter. 10.12% of the stock is currently owned by institutional investors and hedge funds.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing treatments for serious diseases, with a focus on preeclampsia and neurological conditions. Its lead candidate, DM199 (rinvecalinase alfa), is a recombinant form of human tissue kallikrein-1, an enzyme involved in regulating blood flow. DiaMedica is investigating DM199 for acute ischemic stroke and preeclampsia; it remains an investigational drug and is not approved for commercial use. The company is headquartered in Minneapolis, Minnesota, and conducts clinical development of its therapies.